Hemophilia B

Hemophilia B

Global Hemophilia B Market to Reach US$6.4 Billion by 2030

The global market for Hemophilia B estimated at US$3.8 Billion in the year 2023, is expected to reach US$6.4 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2023-2030. Moderate Severity Disease, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Mild Severity Disease segment is estimated at 8.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$989.1 Million While China is Forecast to Grow at 7.5% CAGR

The Hemophilia B market in the U.S. is estimated at US$989.1 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.

Global Hemophilia B Market - Key Trends and Drivers Summarized

Hemophilia B, also known as Christmas disease, is a rare genetic bleeding disorder caused by a deficiency of factor IX, a protein essential for blood clotting. This condition primarily affects males due to its X-linked recessive inheritance pattern, with females typically being carriers. Hemophilia B can vary in severity, with symptoms ranging from mild to severe bleeding episodes, often triggered by injuries or surgeries. Spontaneous bleeding into joints and muscles is a common complication, leading to pain, swelling, and long-term joint damage if not properly managed. The diagnosis is confirmed through blood tests that measure factor IX activity, and genetic testing can identify carriers and inform family planning decisions. Treatment usually involves regular infusions of recombinant or plasma-derived factor IX concentrates to prevent and control bleeding episodes, greatly improving the quality of life for those affected.

Advancements in medical research have significantly improved the management and understanding of Hemophilia B. Gene therapy has emerged as a promising treatment option, aiming to provide a one-time cure by delivering functional copies of the factor IX gene to the liver, where it can produce the necessary clotting factor. Early clinical trials have shown encouraging results, with patients achieving sustained levels of factor IX activity and a substantial reduction in bleeding episodes. Additionally, extended half-life factor IX products, which require less frequent dosing, have been developed, offering greater convenience and adherence to treatment regimens. These innovations, along with enhanced diagnostic techniques and comprehensive care programs, are transforming the landscape of Hemophilia B management, enabling individuals to lead more active and fulfilling lives.

The growth in the Hemophilia B treatment market is driven by several factors. Technological advancements, such as gene therapy and extended half-life clotting factor products, are providing more effective and convenient treatment options. The increasing prevalence of Hemophilia B, coupled with greater awareness and diagnosis rates, is expanding the patient pool seeking treatment. Improved healthcare infrastructure and access to specialized care in emerging economies are also contributing to market growth. Furthermore, patient advocacy groups and educational initiatives are playing a crucial role in promoting early diagnosis and treatment adherence. The shift towards personalized medicine, where treatments are tailored to individual genetic profiles, is another key driver, enhancing the efficacy and safety of therapies. As pharmaceutical companies invest in research and development, the pipeline of novel therapies continues to grow, promising further advancements in the management of Hemophilia B.

Select Competitors (Total 53 Featured) -

• Bayer AG
• Be Biopharma, Inc.
• Centessa Pharmaceuticals Plc
• CSL
• Freeline Therapeutics
• Grifols USA, LLC
• Intellia Therapeutics, Inc.
• LFB Biotechnologies
• Medexus Pharma, Inc. (IXINITY )
• novoMEDLINK
• Pfizer, Inc.
• Spark Therapeutics, Inc.
• Swedish Orphan Biovitrum AB (Sobi)
• Takeda Pharmaceutical Company
• uniQure N.V.;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.